KRAS and neoplasm: PDX models developed represented similar genomic (e.g., ARID1A, PIK3CA, KRAS etc.)and protein (PAX8, ARID1A, napsin A, racemase) profiles to the native patient tumor from which they were derived supporting use of these models as surrogates of the patient tumor.